Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population

International Journal of Biological Markers

Volumn 23, Issue 3, 2008, Pages 192-197

  Venkitaraman, R ^a   Thomas, K ^b   Grace, P ^c   Dearnaley, D ^a   Horwich, A ^a   Huddart, R ^a   Parker, Chris C ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c HFL Limited   (United Kingdom)

Author keywords

Active Surveillance; Phytoestrogen; Prostate

Indexed keywords

DAIDZEIN; ENTEROLACTONE; EQUOL; GENISTEIN; PHYTOESTROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; DISEASE ASSOCIATION; HISTOPATHOLOGY; HORMONE URINE LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; UNITED KINGDOM; BIOPSY; BIOSYNTHESIS; DIET SUPPLEMENTATION; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; TREATMENT OUTCOME; URINE;

AGED; BIOPSY; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PHYTOESTROGENS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 58149377800     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1500     Document Type: Article

References (26)

1. Parker C. Active surveillance of early prostate cancer: rationale, initial results and future developments. Prostate Cancer Prostatic Dis 2004; 7: 184-7.
2. Klotz LH. Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol 2005; 12 (Suppl 2): 21-4.
3. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16-21.
4. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35.
5. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7.
6. Venkitaraman R, Norman A, Woode-Amissah R, et al. Predictors of histological disease progression in untreated, localized prostate cancer. J Urol 2007; 178: 833-7.
7. Jarred RA, Keikha M, Dowling C, et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002; 11: 1689-96.
8. Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003; 47: 111-7.
9. Dalais FS, Meliala A, Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004; 64: 510-5.
10. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003; 12: 665-8.
11. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004; 59: 141-7.
12. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9: 553-7.
13. Brett T. Prostate cancer. What part does diet play? Aust Fam Physician 2000; 29: 1122-4.
14. Schroder FH, Roobol MJ, Boeve ER, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005; 48: 922-30; discussion 930-1.
15. Pendleton JM, Tan WW, Anai S, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008; 8: 132.
16. Grace PB, Mistry NS, Carter MH, Leathem AJ, Teale P. High throughput quantification of phytoestrogens in human urine and serum using liquid chromatography/tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 138-46.
17. Grace PB, Taylor JI, Low YL, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition-Norfolk. Cancer Epidemiol Biomarkers Prev 2004; 13: 698-708.
18. Adams KF, Chen C, Newton KM, Potter JD, Lampe JW. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2004; 13: 644-8.
19. Urban D, Irwin W, Kirk M, et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 2001; 165: 294-300.
20. Atkinson C, Skor HE, Fitzgibbons ED, et al. Overnight urinary isoflavone excretion in a population of women living in the United States, and its relationship to isoflavone intake. Cancer Epidemiol Biomarkers Prev 2002; 11: 253-60.
21. Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002; 132: 3168-71.
22. Pumford SL, Morton MM, Turkes A, Griffiths K. Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry. Ann Clin Biochem 2002; 39: 281-92.
23. Strom SS, Yamamura Y, Duphorne CM, et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer 1999; 33: 20-5.
24. Gu L, Laly M, Chang HC, et al. Isoflavone conjugates are underestimated in tissues using enzymatic hydrolysis. J Agric Food Chem 2005; 53: 6858-63.
25. Venkitaraman R, Norman AR, Iqbal J, et al. Clinical implications of introducing a new PSA assay. Int Urol Nephrol 2008; 40: 657-61.
26. Venkitaraman R, Norman A, Woode-Amissah R, et al. Prostate-specific antigen velocity in untreated, localized prostate cancer. BJU Int 2008; 101: 161-4.